Edwards Lifesciences Corporation (NYSE:EW) Shares Sold by Atria Wealth Solutions Inc.

Atria Wealth Solutions Inc. cut its stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 81.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 6,662 shares of the medical research company's stock after selling 29,763 shares during the quarter. Atria Wealth Solutions Inc.'s holdings in Edwards Lifesciences were worth $483,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Vega Investment Solutions acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at $27,000. Global X Japan Co. Ltd. raised its position in Edwards Lifesciences by 116.1% in the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after acquiring an additional 216 shares in the last quarter. Tradewinds Capital Management LLC raised its position in Edwards Lifesciences by 102.5% in the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock worth $29,000 after acquiring an additional 205 shares in the last quarter. Rossby Financial LCC purchased a new position in shares of Edwards Lifesciences in the first quarter valued at $29,000. Finally, Costello Asset Management INC purchased a new position in shares of Edwards Lifesciences in the first quarter valued at $29,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

Shares of NYSE EW traded up $0.08 during trading on Friday, reaching $78.26. The stock had a trading volume of 2,620,544 shares, compared to its average volume of 4,877,332. Edwards Lifesciences Corporation has a one year low of $64.00 and a one year high of $83.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The stock has a market cap of $45.95 billion, a PE ratio of 11.26, a P/E/G ratio of 3.78 and a beta of 1.08. The firm's 50 day moving average price is $77.13 and its two-hundred day moving average price is $74.41.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. The business had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%. The business's quarterly revenue was up 11.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.70 EPS. On average, research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 4,114 shares of the company's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the transaction, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. This represents a 15.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 2,570 shares of the company's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $77.40, for a total value of $198,918.00. Following the transaction, the vice president owned 50,356 shares of the company's stock, valued at approximately $3,897,554.40. The trade was a 4.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 17,134 shares of company stock valued at $1,311,745 in the last 90 days. Corporate insiders own 1.29% of the company's stock.

Wall Street Analyst Weigh In

EW has been the topic of a number of analyst reports. Robert W. Baird increased their price objective on Edwards Lifesciences from $78.00 to $79.00 and gave the company a "neutral" rating in a research note on Friday, July 25th. BTIG Research raised Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price objective on the stock in a research note on Tuesday, July 29th. Citigroup reaffirmed a "buy" rating and issued a $95.00 price objective (up from $84.00) on shares of Edwards Lifesciences in a research note on Thursday, May 22nd. Wall Street Zen raised Edwards Lifesciences from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on Edwards Lifesciences from $85.00 to $94.00 and gave the stock a "buy" rating in a research report on Friday, July 25th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, thirteen have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $85.90.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.